Australia’s active vaccine safety system
Data on this page show the responses of individuals (or their parent/carer) aged 2 years to younger than 5 years who received an intranasal live attenuated (nasal spray) influenza vaccine in 2026 and completed an AusVaxSafety survey sent in the days following vaccination.
Nasal spray influenza vaccines currently in use in this age group include:
These data provide a profile of what to expect in the days following your child’s influenza vaccination and can assist in planning for vaccination.
Data on this page will be updated weekly throughout the 2026 influenza season.
AusVaxSafety's active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration.
Further information and resources on the 2026 influenza vaccines are available on the NCIRS influenza immunisation webpage.
